NCT01205724 - Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Congenital Bleeding DisorderHaemophilia A

Interventions

DRUG

turoctocog alfa pegol

Single dose (low) administered intravenously (into the vein)

DRUG

turoctocog alfa pegol

Single dose (medium) administered intravenously (into the vein)

DRUG

turoctocog alfa pegol

Single dose (high) administered intravenously (into the vein)

Trial Locations (18)

8091

Novo Nordisk Investigational Site, Zurich

19104

Novo Nordisk Investigational Site, Philadelphia

21287

Novo Nordisk Investigational Site, Baltimore

30625

Novo Nordisk Investigational Site, Hanover

35100

Novo Nordisk Investigational Site, Bornova-IZMIR

35392

Novo Nordisk Investigational Site, Giessen

36100

Novo Nordisk Investigational Site, Vicenza

40536

Novo Nordisk Investigational Site, Lexington

50134

Novo Nordisk Investigational Site, Florence

52242

Novo Nordisk Investigational Site, Iowa City

60590

Novo Nordisk Investigational Site, Frankfurt/M.

77030

Novo Nordisk Investigational Site, Houston

634 8522

Novo Nordisk Investigational Site, Kashihara-shi, Nara

466 8560

Novo Nordisk Investigational Site, Nagoya-shi, Aichi

160 0023

Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo

NW3 2QG

Novo Nordisk Investigational Site, London

SE1 7EH

Novo Nordisk Investigational Site, London

M13 9WL

Novo Nordisk Investigational Site, Manchester